TITLE:

Synthesis and characterization of the amyloid β 40 dimer model with a linker at position 30 adjacent to the intermolecular β -sheet region.

AUTHOR(S):

Murakami, Kazuma; Suzuki, Takashi; Hanaki, Mizuho; Monobe, Yoko; Akagi, Ken-Ichi; Irie, Kazuhiro

CITATION:

Murakami, Kazuma ...[et al]. Synthesis and characterization of the amyloid β 40 dimer model with a linker at position 30 adjacent to the intermolecular β -sheet region.. Biochemical and biophysical research communications 2015, 466(3): 463-467

ISSUE DATE:

2015-10-23

URL:

<http://hdl.handle.net/2433/202905>

RIGHT:

© 2015. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>; The full-text file will be made open to the public on 23 October 2016 in accordance with publisher's 'Terms and Conditions for Self-Archiving'; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。 ; This is not the published version. Please cite only the published version.

Synthesis and characterization of the amyloid β 40 dimer model with a linker at position 30 adjacent to the intermolecular β -sheet region

Kazuma Murakami^a, Takashi Suzuki^a, Mizuho Hanaki^a, Yoko Monobe^b, Ken-ichi Akagi^b, and Kazuhiro Irie^{a,*}

^a*Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan*

^b*National Institute of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan*

*Corresponding Author

Kazuhiro Irie, Ph.D., Tel: +81-75-753-6281. Fax: +81-75-753-6284.

Email: irie@kais.kyoto-u.ac.jp.

Abstract

Amyloid fibrils in senile plaque mainly consist of the 40-mer and 42-mer amyloid β -proteins ($A\beta_{40}$ and $A\beta_{42}$). Although $A\beta_{42}$ plays more important role in the pathogenesis of Alzheimer's disease (AD), $A\beta_{40}$ could be involved in the progression of AD pathology because of its large amount. Recent studies revealed that variable sizes of $A\beta$ oligomers contributed to the neuronal death and cognitive dysfunction. However, how large oligomeric species are responsible for AD pathogenesis remains unclear. We previously proposed a toxic dimer model of $A\beta$ with turn structure at positions 22 and 23 using solid-state NMR and systematic proline replacement. Based on this model, we herein show the synthesis and biological activities of an E22P- $A\beta_{40}$ dimer at position 30, which was connected to L,L-2,6-diaminopimelic acid. The E22P- $A\beta_{40}$ dimer formed stable 6~8-mer oligomers without amyloid fibrils, but was not neurotoxic on human neuroblastoma cells. On the other hand, E22P- $A\beta_{40}$ generated high molecular-weight oligomers into fibrils, and showed the neurotoxicity. These results suggest that such kind of $A\beta_{40}$ dimer with a parallel β -sheet might not be pathological.

Highlights

- E22P-A β 40 dimer with turn at positions 22 and 23 was synthesized.
- The cross-linkage at position 30 by optically active L,L-DAP was adopted in the dimer.
- E22P-A β 40 dimer formed 6~8-mer oligomers without fibrils, but was not neurotoxic.
- A β 40 dimer with a parallel β -sheet might not be related to Alzheimer's pathology.

Keywords

Alzheimer's disease, amyloid β -protein, dimer, oligomer, neurotoxicity.

Abbreviations

A β , amyloid β ; AD, Alzheimer's disease; L,L-DAP, L,L-2,6-diaminopimelic acid; HPLC, high performance liquid chromatography; MALDI-TOF-MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; NMR, nuclear magnetic resonance; PBS, phosphate buffered saline; TEM, transmission electron microscopy; Th-T, thioflavin-T.

1. Introduction

In Alzheimer's disease (AD), amyloid fibrils form senile plaques that mainly consist of 40- and 42-residue amyloid β -proteins (A β 40 and A β 42) [1]. A β 42 is regarded as the leading cause of AD because its aggregative ability and neurotoxicity are more potent than those of A β 40 [2]. In contrast, A β 40 could be involved in the progression of AD pathology because of its large amount. Accumulating evidence has shown that the soluble oligomeric assembly of A β is more exclusively implicated in neuronal death and cognitive dysfunction than insoluble fibrils and protofibrils [3,4]. "Aggregation" in this context is defined as the change from A β monomers into amyloid fibrils *via* oligomers and protofibrils. Since A β 42 only weakly associates with A β 40 [5,6], homogeneous oligomers of A β 42 or A β 40 form more easily than the corresponding heterogeneous oligomers. The minimum unit of these oligomers, which have been divided into low molecular-weight oligomers (2~12-mer) and high molecular-weight oligomers (24~100-mer), is considered to be a dimer or trimer (2 or 3 x *n*-mer) [7]. However, how large oligomeric species of A β are responsible for the pathogenesis of AD remains unknown.

Our previous study using solid-state NMR [8] and systematic proline replacement [9] identified a toxic conformer of A β 42 with a turn structure at Glu22 and Asp23, in which the residues at positions Gln15~Ala21 and Val24~Ile32 took part in the intermolecular parallel β -sheet of A β 42 aggregates. Moreover, the C-terminal hydrophobic core formed by another turn at Gly38 and Val39 together with the intramolecular β -sheet (Met35~Gly37 and Val40~Ala42) accelerated the aggregation (oligomerization) of A β 42 [10]. Based on these findings, we proposed a structural model for a toxic dimer of A β 42 with a turn at Glu22 and Asp23 as shown in Figure 1A. Regarding the aggregates of A β 40, the most abundant species among A β [2], both A β 40 and A β 42 would have the turn structure at positions 22 and 23 together with the intermolecular parallel β -sheet, whereas the C-terminal hydrophobic core is absent in the A β 40 aggregates because of its lower hydrophobicity based on Wetzel's model [11].

Practical synthesis of A β dimers have thus far been limited to A β 40 dimers due to the

intrinsic potent aggregative ability of A β 42 dimers during the synthesis and preparation. For example, Kok *et al.* [12] reported the synthesis of a dityrosine cross-linked A β 42 dimer at position 10; however, its biological activity was not tested due to the insufficiently low amounts obtained. Based on the elevated levels of dityrosine-linked A β dimers in the brains and blood of AD patients, Kok *et al.* synthesized two dimer models of A β 40, in which dityrosine [12] or bifunctional 2,6-diaminopimelic acid (DAP) as “a diastereomeric mixture” [13] was incorporated at position 10 instead of Tyr10. Both models facilitated the production of fibrils in spite of the formation of globular aggregates [12,13] associated with neurotoxicity of the dityrosine-linked A β 40 dimer [12]. The dityrosine-linked A β 40 dimer synthesized by Walsh and co-workers also formed typical amyloid fibrils, even though it impaired long-term potentiation in rats *in vivo* [14]. The disulfide-linked A β 40 dimer at Ser26 inhibited long-term potentiation [15,16], but did not appear to be physiologically relevant to the pathology of AD.

Since A β 40 dimers connected adjacent to the intermolecular β -sheet region have not yet been examined, we synthesized a new dimer model of E22P-A β 40 (Fig. 1B) with the toxic turn, in which position 30 was linked to L,L-2,6-diaminopimelic acid (L,L-DAP; Fig. 1C), not to the diastereomeric mixture [13], in order to investigate the effects of dimerization on its biological activity. Wild-type A β 40 was negligibly neurotoxic, whereas E22P-A β 40 was neurotoxic, albeit 10-fold less than wild-type A β 42 [17]. Ala30 was selected as the linking position because our previous solid-state NMR studies using rotational resonance (R2) revealed that this residue in E22K-A β 42 aggregates (Italian mutant) was proximal (< 6 Å) [18].

2. Material and methods

2.1. Synthesis of the E22P-A β 40 dimer.

L,L-DAP (Fig. 1C) was synthesized according to the protocol established by Paradisi *et al.* [19] with slight modifications [20]. L,L-DAP was obtained from (*S*)- α -phenylethylamine in 6 steps (2.5 % yield). The structure of L,L-DAP was confirmed

by EI-MS, HR-FABMS (JMS-600H; JEOL, Tokyo, Japan), and ^1H NMR (AVANCE III 400 and 500; Bruker, Rheinstetten, Germany, ref. DHO = 4.79 ppm, D_2O): δ 1.46 (2H, m), 1.91 (4H, m), 3.77 (2H, t, $J = 5.9$ Hz) ppm. The specific rotation (P-2200; Jasco, Tokyo, Japan) of L,L-DAP was similar to that reported previously; $[\alpha]_{\text{D}}^{25}$: + 37.6° (c 0.96, 1N HCl, 28 °C), ref. $[\alpha]_{\text{D}}^{25}$: + 42.1° (c 0.96, 1N HCl) [19]. The amino groups of L,L-DAP were protected with Fmoc for the solid-phase synthesis of the E22P-A β 40 dimer; ^1H NMR (ref. $\text{CD}_2\text{HOD} = 3.31$ ppm, CD_3OD): δ 1.54 (2H, m), 1.74 (2H, m), 1.88 (2H, m), 4.16 (4H, m), 4.30 (4H, m), 7.28 (4H, m), 7.34 (4H, t, $J = 7.0$ Hz), 7.63 (4H, m), 7.75 (4H, d, $J = 7.4$ Hz) ppm.

The E22P-A β 40 dimer (Fig. 1B) was synthesized in a stepwise fashion on 0.1 mmol of preloaded Fmoc-L-Val-PEG-PS resin by PioneerTM (Applied Biosystems; Foster City, CA, USA) using the Fmoc method, as described elsewhere [21]. Briefly, after the completion of chain elongation and cleavage from the resin, the crude peptide was precipitated by diethylether, followed by purification using HPLC on a YMC-Pack PROTEIN-RP column (20 mm i.d. x 150 mm; YMC, Kyoto, Japan) with elution at 8.0 mL/min by a 70-min linear gradient of 20-60% CH_3CN containing 0.1% trifluoroacetic acid. Subsequent purification was carried out using YMC-Pack ODS-A (20 mm i.d. x 150 mm; YMC) with elution at 8.0 mL/min by an 80-min linear gradient of 20-60% CH_3CN containing 0.1% trifluoroacetic acid. Lyophilization gave a pure peptide, the purity of which was confirmed by HPLC (>98%, 2.8% yield). The molecular weight of the E22P-A β 40 dimer was confirmed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS, Bruker Ultraflex); m/z , calculated: 8608.80; found: 8609.55 $[\text{MH}]^+$.

2.2 Thioflavin-T (Th-T) assay.

The aggregative ability of each A β was evaluated by thioflavin-T (Th-T; Sigma, St. Louis, MO, USA) fluorescence assay developed by Naiki and Gejyo [22]. The procedure was described elsewhere [21]. Each A β was dissolved in 0.1% NH_4OH at 250 μM , followed by 10-fold dilution with phosphate buffered saline (PBS: 50 mM sodium

phosphate and 100 mM NaCl, pH 7.4) at the final concentration of 25 μ M. After incubation at 37 °C for the desired period, 2.5 μ L of the reaction solution was added to 250 μ L of 5.0 μ M Th-T in 5.0 mM Gly-NaOH (pH 8.5), followed by the measurement of fluorescence at 430 nm excitation and 485 nm emission using a microplate reader (Fluoroskan Ascent; Thermo Scientific, Rockford, IL, USA).

2.3. Transmission electron microscopy (TEM).

The aggregates of each A β were examined under a H-7650 electron microscope (Hitachi, Ibaraki, Japan). The experimental procedure was described elsewhere [21]. After the supernatant was removed from pellets obtained in Th-T assay, resultant aggregates were then suspended in water (20 μ L) by gentle vortex mixing, and centrifuged 13,000 rpm for 3 min. These suspensions were applied to a 200 mesh formvar-coated copper grid (Nissin EM, Tokyo, Japan), and allowed to dry in air for 5 min before being negatively stained for 2 min with 2% uranyl acetate, and subsequently subjected to microscope.

2.4. Size exclusion chromatography.

Each A β solution, as prepared in Th-T assay, was incubated at 37°C. After the solution was collected temporally and centrifuged at 15,000 rpm at 4°C for 10 min, 60 μ L of the supernatant was analyzed by size exclusion chromatography on the Superdex75 10/300GL column (10 mm i.d. x 300 mm; GE Healthcare, Fairfield, CT, USA) with elution at 0.6 mL/min by filtered- and degassed-PBS, attached to a Waters LC system with a 2489 UV/Visible detector and 1525 binary HPLC pump controlled by EmpowerTM3 software (Waters, Taunton, MA, USA). The peptide was detected by absorbance at 220 nm. Calibration curves of size exclusion columns were constructed by dextran standards (Mp: mean peak molecular weight, 43,500; 21,400; 9,890; 4,440 Da) (Sigma) together with Blue dextran 2000 (GE Healthcare) as an indicator of the void volume (V_o).

2.5. MTT assay.

SH-SY5Y cells, maintained in Dulbecco's modified eagle medium (DMEM; Wako, Osaka, Japan) containing 10% fetal bovine serum, were used as one of the typical neuronal cell models to estimate the neurotoxicity of each A β with slight modifications to the described method [21]. In brief, each A β was dissolved in 0.1% NH₄OH to 220 μ M. The resultant peptide solution (10 μ L) diluted with 0.1% NH₄OH to appropriate final concentrations (10⁻⁷, 10⁻⁶, 10^{-5.5}, 10⁻⁵ M) in the medium was added to 100 μ L of the culture medium of near-confluent cells (10⁴ cells/well). After being treated at 37°C for 48 hr, 10 μ L of 5 mg/mL MTT (Sigma) was added to cells, followed by an incubation for 4 h at 37°C. After the removal of 70 μ L of the culture medium, the cell lysis buffer (100 μ L/well; 10% SDS, 0.01 M NH₄Cl) was subsequently added to the cells. The cell lysate was then incubated overnight in the dark at room temperature before measurements at 595 nm with a microplate reader (MultiScan JX; Thermo Scientific, Waltham, MA, USA). Absorbance obtained by the addition of vehicle (0.1% NH₄OH) was taken as 100%.

2.6. Statistical analysis.

All data are presented as the mean $\pm$ SEM. The differences were analysed with one-way analysis of variance (ANOVA), followed by Bonferroni's test or unpaired Student's *t*-test. These tests were implemented within GraphPad Prism software (version 5.0d). *p* values <0.05 were considered significant.

3. Results

3.1. Synthesis of the E22P-A β 40 dimer

After several trials and errors, we adopted L,L-DAP (Fig. 1C) as a covalent cross-linker of E22P-A β 40 with significant neurotoxicity, albeit 10-fold less than wild-type A β 42 [17]. Solid-phase synthesis using Fmoc-L,L-DAP at position 30, adjacent to the intermolecular β -sheet region of A β 40 aggregates, provided a pure and sufficient amount of the E22P-A β 40 dimer as shown in Fig. 1B. (purity: >98%, 2.8% yield). Given E22P mutant as a toxic conformer surrogate, a monoclonal antibody (11A1) [23], previously developed

against the toxic conformer of A β with turn at positions 22 and 23, reacted with the E22P-A β 40 dimer (data not shown). We further attempted to synthesize a E22P-A β 40 dimer doubly cross-linked at positions 17 and 30 using L,L-DAP in order to enhance the stability of the toxic conformation of E22P-A β 40 dimer, but such an attempt was disappointing (data not shown).

3.2. *The ability of the E22P-A β 40 dimer to form fibrils*

The aggregative ability of the E22P-A β 40 dimer with a linker at position 30 was estimated using Th-T, a reagent that fluoresces when bound to A β aggregates, and transmission electron microscopy (TEM). As shown in Figure 2A, E22P-A β 40 aggregated with a lag time of ~8 h and a maximum fluorescence value after being incubated for 24 h. The wild-type A β 40 did not aggregate after a 24-h incubation under the same conditions, as reported previously [21]. In contrast, the fluorescence of the E22P-A β 40 dimer remained almost unchanged even after a 336-h incubation (14 days) (Fig. 2A). These results were consistent with TEM results showing that globular aggregates, not fibrils, were predominantly detected in the E22P-A β 40 dimer (Fig. 2B). On the other hand, the typical amyloid fibrils together with high molecular-weight oligomeric aggregates were formed in E22P-A β 40 even after 2 days (Fig. 2B). These results indicated that the E22P-A β 40 dimer had the ability to form a soluble assembly and globular oligomers, but not fibrils.

3.3. *The ability of the E22P-A β 40 dimer to form oligomers*

Oligomerization of the E22P-A β 40 dimer was analysed further using size exclusion chromatography. As a control reference, Figure 3A showed that the soluble peak corresponding to the monomer of E22P-A β 40 time-dependently decreased, and almost disappeared after an incubation for 16 h; this result implied that E22P-A β 40 directly formed insoluble fibrils, as observed in Figure 2B. On the other hand, the E22P-A β 40 dimer formed stable oligomers of 6~8-mer during incubation for 4~48 hr (Fig. 3B).

Although the assembly size of the predominant oligomers after 168-h and 336-h incubations exceeded 10-mer, it was difficult to calculate this correctly because of the limitation of the size exclusion column (Superdex75 10/300GL) used in this experiment.

3.4. The neurotoxicity of the E22P-A β 40 dimer on SH-SY5Y cells

The neurotoxicity of the E22P-A β 40 dimer in human neuroblastoma SH-SY5Y cells, one of the typical models of neuronal cell cultures, was measured using the MTT assay. After being incubated for 48 h, the viability of cells treated with E22P-A β 40 (3.2 μ M = $10^{-5.5}$ M) significantly decreased, which indicated E22P-A β 40 to be neurotoxic as reported previously in PC12 cells [21] (Fig. 4A). In contrast, the neurotoxicity of the E22P-A β 40 dimer was not observed, even at 10 μ M ($10^{-5.5}$ M), as shown in Fig. 4B. Ono *et al.* prepared a mixture of dimers, trimers, and tetramers of wild-type A β 40, using photo-induced cross-linking of unmodified protein (PICUP) technology that mainly bound covalently at Tyr10 [24], and demonstrated that each oligomer of A β 40 exhibited the neurotoxicity in a size-dependent manner [25]. However, the marginal toxicity of the PICUP-induced A β 40 dimer did not seem to basically contradict our results in Figure 4B.

4. Discussion

We demonstrated that the dimer model of E22P-A β 40 (Fig. 1B) linked at position 30 adjacent to the intermolecular β -sheet region in the aggregates formed stable low molecular-weight oligomers, mainly consisting of 6~8-mers, that did not extend to fibrils. However, this dimer model was less neurotoxic than the corresponding E22P-A β 40 monomer with the toxic turn at positions 22 and 23, suggesting that such kind of the dimer model in Figure 1B, which is the minimum structure of non-toxic A β 40 fibrils [26], could not be crucially involved in the pathogenesis of AD. Given the significant toxicity of E22P-A β 40, the formation of high molecular-weight oligomers in the case of A β 40 may be required for AD pathology. Although the insignificant toxicity of the E22P-A β 40 dimer does not necessarily deter further investigations on the position of cross-linking, the

synthesis and characterization of dimer models of “more toxic A β 42” appear to be more important. Whether high molecular-weight oligomers or low molecular-weight oligomers derived from A β 42 can contribute to the neurotoxicity will be an attractive issue in the future. Since this study validated optically active L,L-DAP as a useful linker near the intermolecular β -sheet region of A β 40, this strategy may also be applicable to the synthesis of various A β 42 dimer models.

5. Acknowledgements

This study was supported by JSPS KAKENHI Grant Number 26221202 to K.I. and K.M., and by funds for the life science research 2013 from Takeda Science Foundation to K.I. We thank Professor Shunsuke Izumi of the Graduate School of Sciences, Hiroshima University for MALDI-TOF-MS measurements. We also thank Ms. Keiko Uchida of the National Institute of Biomedical Innovation, Health and Nutrition, for her assistance with TEM.

References

- [1] C.L. Masters, G. Simms, N.A. Weinman, G. Multhaup, B.L. McDonald, K. Beyreuther, Amyloid plaque core protein in Alzheimer disease and Down syndrome, *Proc. Natl. Acad. Sci. U.S.A.* 82 (1985) 4245-4249.
- [2] C. Haass, D.J. Selkoe, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β -peptide, *Nat. Rev. Mol. Cell Biol.* 8 (2007) 101-112.
- [3] R. Roychaudhuri, M. Yang, M.M. Hoshi, D.B. Teplow, Amyloid β -protein assembly and Alzheimer disease, *J. Biol. Chem.* 284 (2009) 4749-4753.
- [4] I. Benilova, E. Karran, B. De Strooper, The toxic A β oligomer and Alzheimer's disease: an emperor in need of clothes, *Nat. Neurosci.* 15 (2012) 349-357.
- [5] K. Zou, D. Kim, A. Kakio, K. Byun, J.S. Gong, J. Kim, M. Kim, N. Sawamura, S. Nishimoto, K. Matsuzaki, B. Lee, K. Yanagisawa, M. Michikawa, Amyloid β -protein (A β)1-40 protects neurons from damage induced by A β 1-42 in culture and in rat brain,

- J. Neurochem. 87 (2003) 609-619.
- [6] K. Ono, R. Takahashi, T. Ikeda, M. Yamada, Cross-seeding effects of amyloid β -protein and α -synuclein, J. Neurochem. 122 (2012) 883-890.
- [7] K. Murakami, Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease, Biosci. Biotechnol. Biochem. 78 (2014) 1293-1305.
- [8] Y. Masuda, S. Uemura, R. Ohashi, A. Nakanishi, K. Takegoshi, T. Shimizu, T. Shirasawa, K. Irie, Identification of physiological and toxic conformations in A β 42 aggregates, ChemBioChem 10 (2009) 287-295.
- [9] A. Morimoto, K. Irie, K. Murakami, Y. Masuda, H. Ohigashi, M. Nagao, H. Fukuda, T. Shimizu, T. Shirasawa, Analysis of the secondary structure of β -amyloid (A β 42) fibrils by systematic proline replacement, J. Biol. Chem. 279 (2004) 52781-52788.
- [10] K. Murakami, K. Irie, H. Ohigashi, H. Hara, M. Nagao, T. Shimizu, T. Shirasawa, Formation and stabilization model of the 42-mer A β radical: implications for the long-lasting oxidative stress in Alzheimer's disease, J. Am. Chem. Soc. 127 (2005) 15168-15174.
- [11] A.D. Williams, E. Portelius, I. Kheterpal, J.T. Guo, K.D. Cook, Y. Xu, R. Wetzel, Mapping A β amyloid fibril secondary structure using scanning proline mutagenesis, J. Mol. Biol. 335 (2004) 833-842.
- [12] W.M. Kok, J.M. Cottam, G.D. Ciccotosto, L.A. Miles, J.A. Karas, D.B. Scanlon, B.R. Roberts, M.W. Parker, R. Cappai, K.J. Barnham, C.A. Hutton, Synthetic dityrosine-linked β -amyloid dimers form stable, soluble, neurotoxic oligomers, Chem. Sci. 4 (2013) 4449-4454.
- [13] W.M. Kok, D.B. Scanlon, J.A. Karas, L.A. Miles, D.J. Tew, M.W. Parker, K.J. Barnham, C.A. Hutton, Solid-phase synthesis of homodimeric peptides: preparation of covalently-linked dimers of amyloid β peptide, Chem. Commun. (2009) 6228-6230.
- [14] T.T. O'Malley, N.A. Oktaviani, D. Zhang, A. Lomakin, B. O'Nuallain, S. Linse, G.B. Benedek, M.J. Rowan, F.A. Mulder, D.M. Walsh, A β dimers differ from monomers in

- structural propensity, aggregation paths and population of synaptotoxic assemblies, *Biochem. J.* 461 (2014) 413-426.
- [15] G.M. Shankar, S. Li, T.H. Mehta, A. Garcia-Munoz, N.E. Shepardson, I. Smith, F.M. Brett, M.A. Farrell, M.J. Rowan, C.A. Lemere, C.M. Regan, D.M. Walsh, B.L. Sabatini, D.J. Selkoe, Amyloid- β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory, *Nat. Med.* 14 (2008) 837-842.
- [16] B. O'Nuallain, D.B. Freir, A.J. Nicoll, E. Risse, N. Ferguson, C.E. Herron, J. Collinge, D.M. Walsh, Amyloid β -protein dimers rapidly form stable synaptotoxic protofibrils, *J. Neurosci.* 30 (2010) 14411-14419.
- [17] A. Morimoto, K. Irie, K. Murakami, H. Ohigashi, M. Shindo, M. Nagao, T. Shimizu, T. Shirasawa, Aggregation and neurotoxicity of mutant amyloid β ($A\beta$) peptides with proline replacement: importance of turn formation at positions 22 and 23, *Biochem. Biophys. Res. Commun.* 295 (2002) 306-311.
- [18] Y. Masuda, A. Nakanishi, R. Ohashi, K. Takegoshi, T. Shimizu, T. Shirasawa, K. Irie, Verification of the intermolecular parallel β -sheet in E22K- $A\beta$ 42 aggregates by solid-state NMR using rotational resonance: implications for the supramolecular arrangement of the toxic conformer of $A\beta$ 42, *Biosci. Biotechnol. Biochem.* 72 (2008) 2170-2175.
- [19] F. Paradisi, G. Porzi, S. Rinaldi, S. Sandri, A simple asymmetric synthesis of (+)- and (-)-2,6-diaminopimelic acids, *Tetrahedron: Asymmetry* 11 (2000) 1259-1262.
- [20] S.-D. Cho, S.-Y. Song, K.-H. Kim, B.-X. Zhao, C. Ahn, W.-H. Joo, Y.-J. Yoon, J.R. Falck, D.-S. Shin, One-pot synthesis of symmetrical 1,4-disubstituted piperazine-2,5-diones, *Bull. Korean Chem. Soc.* 25 (2004) 415-416.
- [21] K. Murakami, K. Irie, A. Morimoto, H. Ohigashi, M. Shindo, M. Nagao, T. Shimizu, T. Shirasawa, Neurotoxicity and physicochemical properties of $A\beta$ mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease, *J. Biol. Chem.* 278 (2003) 46179-46187.
- [22] H. Naiki, F. Gejyo, Kinetic analysis of amyloid fibril formation, *Methods Enzymol.*

309 (1999) 305-318.

- [23] K. Murakami, Y. Horikoshi-Sakuraba, N. Murata, Y. Noda, Y. Masuda, N. Kinoshita, H. Hatsuta, S. Murayama, T. Shirasawa, T. Shimizu, K. Irie, Monoclonal antibody against the turn of the 42-residue amyloid β -protein at positions 22 and 23, *ACS Chem. Neurosci.* 1 (2010) 747-756.
- [24] S.K. Maji, R.R. Ogorzalek Loo, M. Inayathullah, S.M. Spring, S.S. Vollers, M.M. Condron, G. Bitan, J.A. Loo, D.B. Teplow, Amino acid position-specific contributions to amyloid β -protein oligomerization, *J. Biol. Chem.* 284 (2009) 23580-23591.
- [25] K. Ono, M.M. Condron, D.B. Teplow, Structure-neurotoxicity relationships of amyloid β -protein oligomers, *Proc. Natl. Acad. Sci. U.S.A.* 106 (2009) 14745-14750.
- [26] A.T. Petkova, Y. Ishii, J.J. Balbach, O.N. Antzutkin, R.D. Leapman, F. Delaglio, R. Tycko, A structural model for Alzheimer's β -amyloid fibrils based on experimental constraints from solid state NMR, *Proc. Natl. Acad. Sci. U.S.A.* 99 (2002) 16742-16747.

Figure legends

Fig. 1. Toxic dimer models of A β 42 and A β 40 with turns at positions 22 and 23.

(A) A toxic dimer model of A β 42 based on our previous structural studies using solid-state NMR and systematic proline replacement. (B) The E22P-A β 40 dimer covalently cross-linked at Ala30 by L,L-DAP, whose structure was based on Wetzel's model [11]. (C) L,L-DAP as a molecular linker

Fig. 2. Analyses of the aggregative abilities of the E22P-A β 40 monomer and dimer to form fibrils.

(A) The Th-T assay of each A β derivative after incubation of the indicated period. ●, E22P-A β 40; ○, the E22P-A β 40 dimer. Data were presented as the mean $\pm$ SEM ($n = 8$). (B) A TEM analysis of A β aggregates formed from E22P-A β 40 and the E22P-A β 40 dimer after incubation of the indicated period. Scale bar = 100 nm. *Left*, E22P-A β 40; *Right*, the E22P-A β 40 dimer.

Fig. 3. Analyses of the abilities of the E22P-A β 40 monomer and dimer to form soluble oligomers.

The ability of each A β derivative to form soluble oligomers was evaluated by size exclusion chromatography after incubation of the indicated period. (A) E22P-A β 40; (B) the E22P-A β 40 dimer. The peptide was detected by absorbance at 220 nm. The size of molecular marker (kDa) is shown. V_o : void volume. *: artifact.

Fig. 4. Neurotoxicity of the E22P-A β 40 monomer and dimer in SH-SY5Y cells.

The near-confluent SH-SY5Y cells (10^4 cells/well) were treated with the E22P-A β 40 monomer or dimer (10^{-7} , 10^{-6} , $10^{-5.5}$, 10^{-5} M) in DMEM medium containing 10% fetal bovine serum before incubation at 37°C for 48 hr. Data were presented as the mean $\pm$ SEM ($n = 3$). Absorbance obtained by the addition of vehicle (0.1% NH_4OH) was taken as 100%. * $p < 0.05$ versus vehicle (Veh).

Fig. 1. Murakami, K. *et al.*

Fig. 2. Murakami, K. *et al.*

Fig. 3. Murakami, K. *et al.*

Fig. 4. Murakami, K. *et al.*